There is a noted increase in allergic diseases in children, with Atopic Dermatitis (AD) being one of the most prevalent. The course of AD is closely linked to the state of the gastrointestinal tract, and Acute Intestinal Infection (AII) often acts as a trigger, causing an exacerbation of dermatitis.

The study aims to compare the efficacy of three different groups of enterosorbents—colloidal silicon dioxide, polymethylsiloxane polyhydrate, and dioctahedral smectite—in the treatment of acute intestinal infection in children who also suffer from atopic dermatitis.

Methodology and Key Findings

Seventy-five children diagnosed with "acute intestinal infection" and co-occurring atopic dermatitis were observed. The patients were divided into three groups, each receiving one of the three enterosorbents in addition to basic therapy.

Key conclusions drawn from the study:

Speed of Symptom Relief: In the groups receiving colloidal silicon dioxide (e.g., Polysorb MP) and dioctahedral smectite (e.g., Smecta), most symptoms of gastroenteritis (diarrhea, vomiting, fever) were relieved significantly faster (by the end of the third day of treatment) compared to the group receiving polymethylsiloxane polyhydrate.

Effect on Atopic Dermatitis: Children who received colloidal silicon dioxide and polymethylsiloxane polyhydrate showed a more significant and confirmed reduction in the severity of atopic dermatitis manifestations (based on the SCORAD index) and the level of Immunoglobulin E (IgE) upon discharge, compared to the dioctahedral smectite group.

Optimal Choice: Based on a comprehensive assessment of efficacy, which included rapid relief of the infectious process and a positive effect on skin manifestations and allergic markers, colloidal silicon dioxide was identified as the optimal enterosorbent for the initial therapy of acute intestinal infection in children with co-occurring atopic dermatitis.

Full Article:To view the complete study data, including detailed tables and analysis, please follow the link to the full article: Full Article